Syed Gardezi, MD
Internal Medicine · Richmond, TXNPI 1689637464
Payments from drug & device makers
Across 558 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- GSK$1K
- Lilly USA, LLC$951
- AstraZeneca$732
- Bayer$683
- Amgen$551
- plus $4K from 33 others
What the payments were for
- Food & beverage$9,27899%
- Education$1131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 87 | $1,379 |
| GSK | 73 | $1,184 |
| Lilly USA, LLC | 58 | $951 |
| AstraZeneca | 48 | $732 |
| Bayer | 40 | $683 |
| Amgen | 29 | $551 |
| AbbVie(2 entities) | 34 | $518 |
| Amarin Pharma, Inc. | 27 | $512 |
| Merck | 31 | $434 |
| Boehringer Ingelheim | 22 | $407 |
| Pfizer | 23 | $389 |
| Teva Pharmaceuticals USA, Inc. | 14 | $278 |
| Novartis | 13 | $176 |
| Johnson & Johnson | 10 | $172 |
| Exact Sciences | 8 | $152 |
| Medtronic | 1 | $146 |
| Shield Therapeutics Inc | 6 | $104 |
| Dexcom, Inc. | 3 | $74 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Genentech USA, Inc. | 2 | $47 |
| Mylan Specialty L.p. | 2 | $44 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Circassia Inc. | 2 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Amniox Medical, Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Althera Pharmaceuticals LLC | 1 | $21 |
| Abbott | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Medinc Of Texas | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Fidia Pharma USA Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,392 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $249,160 |
| JardianceEmpagliflozin | 151 | $183,148 |
| MounjaroTirzepatide | 150 | $165,295 |
| EliquisApixaban | 103 | $103,379 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 120 | $80,619 |
| TrulicityDulaglutide | 38 | $68,386 |
| FarxigaDapagliflozin Propanediol | 36 | $45,134 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 24 | $29,022 |
| TivicayDolutegravir Sodium | 11 | $28,743 |
| RybelsusSemaglutide | 14 | $24,779 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $23,729 |
| JanuviaSitagliptin Phosphate | 24 | $23,206 |
| EntrestoSacubitril/Valsartan | 17 | $19,412 |
| Repatha SureclickEvolocumab | 19 | $17,718 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $16,905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,379 | $273,939150 claims |
| Lilly USA, LLCMounjaro, Trulicity | $951 | $233,681188 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $407 | $212,170175 claims |
| PfizerEliquis | $389 | $103,379103 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,184 | $88,709141 claims |
| AstraZenecaFarxiga, Brilinta | $732 | $58,12449 claims |
| MerckJanuvia, Janumet Xr | $434 | $39,45236 claims |
| NovartisEntresto | $176 | $19,41217 claims |
| BayerKerendia | $683 | $12,27613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Richmond
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.